A study by Han et al. showed that sBTLA can block BTLA-HVEM interaction, and in an anti-tumor vaccine model, they found that co-treatment of splenocytes with sBTLA resulted in increased IL-2 and IFN-γ and T cell cytotoxic activity [39]. Here, IL2 is linked to neoplasm.